Table 1.
Epidemiological characteristics of enrolled RASs and susceptibility to DAAs.
| Characteristics | All patients | HIV status | P | |
|---|---|---|---|---|
| HCV-monoinfected | HIV/HCV-coinfected | |||
| N, (%) | 588 | 300 (51.0%) | 288 (49.0%) | |
| Age, years (median, IQR) | 50 (47; 53) | 51 (47; 55) | 49 (46; 53) | < 0.001 |
| Sex, men (n, %) | 475 (80.8) | 236 (78.7) | 239 (83.0) | 0.184 |
| HCV clade (n, %) | ||||
| I | 102 (17.3) | 39 (13.0) | 63 (21.9) | 0.004 |
| II | 486 (82.7) | 261 (87.0) | 225 (78.1) | |
| RASs (n, %) | N = 58 | N = 28 | N = 30 | |
| K24R | 4 (0.7) | 2 (0.7) | 2 (0.7) | – |
| M28A/T/V | 22 (3.7) | 11 (3.7) | 11 (3.8) | – |
| Q30E/H/R | 12 (2.0) | 7 (2.3) | 5 (1.7) | – |
| L31M | 4 (0.7) | 1 (0.3) | 3 (1.0) | – |
| H58D | 2 (0.3) | – | 2 (0.7) | – |
| Y93C/F/H/N | 14 (2.4) | 7 (2.3) | 7 (2.4) | – |
| Double mutations (n, %) | 7 (1.2) | 5 (1.7) | 2 (0.7) | – |
| Patients with reduced susceptibility to DAAs, (n, %) | 50 (8.5) | 22 (7.3) | 28 (9.7) | 0.299 |
| Resistance to DAAs (n, %) | ||||
| DACLATASVIR | 32 (5.4) | 12 (4.0) | 20 (6.9) | 0.116 |
| ELBASVIR | 31 (5.3) | 11 (3.7) | 20 (6.9) | 0.075 |
| LEDIPASVIR | 35 (6.0) | 13 (4.3) | 22 (7.6) | 0.090 |
| OMBITASVIR | 41 (7.0) | 20 (6.7) | 21 (7.3) | 0.766 |
| PIBRENTASVIR | 8 (1.4) | 5 (1.7) | 3 (1.0) | 0.725 |
| VELPATASVIR | 20 (3.4) | 6 (2.0) | 14 (4.9) | 0.069 |
| 1 DAAs | 18 (3.1) | 10 (3.3) | 8 (2.8) | – |
| 2 DAAs | – | – | – | – |
| 3 DAAs | 2 (0.3) | 1 (0.3) | 1 (0.3) | – |
| 4 DAAs | 15 (2.6) | 6 (2.0) | 9 (3.1) | – |
| 5 DAAs | 7 (1.2) | – | 7 (2.4) | – |
| 6 DAAs | 8 (1.4) | 5 (1.7) | 3 (1.0) | – |
| Possibly resistant | 12 (2.0) | 5 (1.7) | 7 (2.4) | – |
IQR, Interquartile range; DAAs, Direct-Acting Antiviral Agents; RASs: relevant resistance-associated substitutions.
Mann–Whitney U test was used for continuous variables; Pearson Chi-Square test or Fisher’s Exact Test were used for categorical variables. All the tests are 2-sided.